Global Ganja Report

Yet again, a scientific study linking cannabis use to psychiatric maladies gets widespread and sensationalistic media play. And once again, the assumptions behind the study are questionable, and the findings are further distorted by irresponsible reportage.

Does daily cannabis use, especially of high-potency "skunk" strains, lead to an increased risk of developing psychosis? Based on recent media coverage, you can be forgiven for thinking so. But you should really take a closer look before you believe the hype.

Counterintuitively, the world's top legal cannabis producer, the United Kingdom, is now importing its first shipments of medicinal cannabis prodccts, from Canada and the Netherlands. This is an advance for the UK medical marijuana program, but a proverbial case of "coals to Newcastle"—pointing to the paradoxes of cannabis globalization.

The World Health Organization has released its long-anticipated recommendation on cannabis scheduling. But rather than removing it from Schedule I of the Single Convention, it only removes it from Schedule IV, where it is also listed. CBD, however, has indeed been de-scheduled entirely.

California's ArcView Market Research and its affiliated BDS Analytics have released a "2019 Update" to the 6th edition of their report on The State of Legal Marijuana Markets, which was published back in June. The Update takes stock of events in the second half of the year, and anticipates that worldwide spending on legal cannabis will grow 39.1% to $17 billion in 2019.

In what is starting to smell like an anti-cannabis media campaign, headlines erupt this week on the possible deleterious effects of cannabis on the developing brains of young teens. Again, the accounts are one-sided—and the political assumptions behind them flawed.

Recent days have seen successive stories in the media on the supposed mental health hazards of cannabis—seeming to signal a backlash to recent gains in normalizing the plant and overcoming the stigma.

The claim that cannabis causes "mental illness" rears its dubious head like clockwork every few years, and this latest round has occasioned a virtual media frenzy—a seeming backlash to the recent advances in normalization of the herb and its aficionados. Scratching the claims, however, reveals more hype than rigor.

The headlines are all too familiar ones, but this time they got very prominent play.

2018 saw historic strides toward the liberation of the cannabis plant, from the proverbial four corners of the Earth—North America to the Antipodes. Canadian legalization garnered big headlines, but there were significant breaks with the global prohibition regime in several other countries—including some seemingly unlikely candidates, in regions where the anti-cannabis stigma is deeply entrenched.

When the United Kingdom announced the historic step of rescheduling cannabis and allowing physicians to prescribe it two months ago, there was concern from patients and advocates as to whether actual herbaceous flower would be allowed, or only extracts. Now the first patient is approved to receive cannabis under the program, and it is indeed to be dried flower. The bad news: with the National Health Service barred by bureaucratic hurdles from providing it, patients are at the mercy of the market—and the price is prohibitive.